Results 21 to 30 of about 36,176 (202)

Management of Atypical Haemolytic Uraemic Syndrome With Triggers: Diagnostic and Treatment Algorithms From an Asia-Pacific Perspective. [PDF]

Nephrology (Carlton)
Management of trigger‐related aHUS in Asia‐Pacific regions. ABSTRACT Complement‐amplifying events/conditions associated with thrombotic microangiopathy (TMA) include pregnancy/postpartum period, severe hypertension, autoimmune diseases, drug exposures, infections and organ transplantation.
Kang HG, Hsu D, Kato N, Kim JS, Okumi M, Tseng MH, Tu KH, Yap DYH, Lim WH.   +8 more
europepmc   +2 more sources

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine

eJHaem, 2021
Acquired thrombotic thrombocytopenic purpura is characterized by the microvascular aggregation of platelets and microangiopathic hemolytic anemia causing ischemia of multiple organs including the brain mainly and less likely the kidney and the heart. The
M. Al‐Ahmad, M. Al-Rasheed, Neveen A. Shalaby   +2 more
semanticscholar   +1 more source

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood Advances, 2020
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and
L. Völker, J. Kaufeld, Wolfgang A. Miesbach, Sebastian Brähler, M. Reinhardt, Lucas Kühne, A. Mühlfeld, A. Schreiber, J. Gaedeke, M. Tölle, W. Jabs, Fedai Özcan, S. Markau, M. Girndt, F. Bauer, T. Westhoff, H. Felten, M. Hausberg, M. Brand, J. Gerth, M. Bieringer, M. Bommer, S. Zschiedrich, J. Schneider, S. Elitok, A. Gawlik, A. Gäckler, A. Kribben, V. Schwenger, U. Schoenermarck, M. Roeder, J. Radermacher, J. Bramstedt, A. Morgner, R. Herbst, Ana Harth, S. Potthoff, C. von Auer, R. Wendt, H. Christ, P. Brinkkoetter, J. Menne   +41 more
semanticscholar   +1 more source

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

New England Journal of Medicine, 2019
BACKGROUND In acquired thrombotic thrombocytopenic purpura (TTP), an immune‐mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis ...
M. Scully, S. Cataland, F. Peyvandi, P. Coppo, P. Knöbl, J. Hovinga, A. Metjian, J. de la Rubia, K. Pavenski, F. Callewaert, Debjit Biswas, H. de Winter, R. Zeldin   +12 more
semanticscholar   +1 more source

Thrombotic Thrombocytopenic Purpura in Dengue Fever

Acta Medica Indonesiana, 2021
Thrombotic thrombocytopenic purpura is a rare but life threatening medical condition. Early recognition and treatment of thrombotic thrombocytopenic purpura is important especially in patients who do not present with the classic pentad to reduce the ...
Tze Yuan Tee, Rizna Abdul Cader
doaj  

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Balkan Medical Journal, 2018
Background: Thrombotic thrombocytopenic purpura is a potentially life-threatening condition. Although the introduction of therapeutic plasma exchange has reduced mortality rates from over 90% to 10%-20%, approximately 40% of patients relapse, and ...
Seniz Öngören, Ayşe Salihoğlu, Tuğçe Apaydın, Sevil Sadri, Ahmet Emre Eşkazan, Muhlis Cem Ar, Tuğrul Elverdi, Zafer Başlar, Yıldız Aydın, Teoman Soysal   +9 more
doaj   +1 more source

Treatment of thrombotic thrombocytopenic purpura

Terapevticheskii arkhiv, 2021
The review discusses approaches to treatment of congenital thrombotic thrombocytopenic purpura (TTP) or Upshaw-Schulman syndrome. In congenital TTP, plasma transfusions are sufficient. Such treatment options as plasma exchange, administration of clotting factor VIII concentrate, recombinant ADAMTS13, are also used.
Gennadii M. Galstyan, Alexei A. Maschan, Elizaveta E. Klebanova, Irina I. Kalinina   +3 more
openaire   +7 more sources

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

Haematologica, 2016
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13.
Wenjing Cao, Huy P. Pham, Lance A. Williams, Jenny McDaniel, Rance C. Siniard, Robin G. Lorenz, Marisa B. Marques, X. Long Zheng   +7 more
doaj   +1 more source

Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background Incidences of immune thrombocytopenic purpura occur in 1 in every 1000–10,000 pregnancies accounting for 3% of all thrombocytopenic pregnancies.
Naser Al-Husban, Oqba Al-Kuran
doaj   +1 more source

Thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2005
This overview summarizes the history of thrombotic thrombocytopenic purpura (TTP) from its initial recognition in 1924 as a most often fatal disease to the discovery in 1997 of ADAMTS-13 deficiency as a major risk factor for acute disease manifestation.
J. A. Kremer Hovinga, Bernhard Lämmle, Lorenzo Alberio   +2 more
openaire   +5 more sources